Cart
sales@molnova.com
β-Amyloid 22-40
CAS No. 1206779-25-0
β-Amyloid 22-40( —— )
Catalog No. M30243 CAS No. 1206779-25-0
This synthetic peptide consists of amino acids 22 to 40 of beta amyloid protein. This peptide sequence is often used in beta amyloid structure and aggregation studies.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product Nameβ-Amyloid 22-40
-
NoteResearch use only, not for human use.
-
Brief DescriptionThis synthetic peptide consists of amino acids 22 to 40 of beta amyloid protein. This peptide sequence is often used in beta amyloid structure and aggregation studies.
-
DescriptionThis synthetic peptide consists of amino acids 22 to 40 of beta amyloid protein. This peptide sequence is often used in beta amyloid structure and aggregation studies.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMembrane Transporter/Ion Channel
-
TargetBeta Amyloid
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1206779-25-0
-
Formula Weight1815.1
-
Molecular FormulaC78H135N21O26S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical NameSequence:{Glu}{Asp}{Val}{Gly}{Ser}{Asn}{Lys}{Gly}{Ala}{Ile}{Ile}{Gly}{Leu}{Met}{Val}{Gly}{Gly}{Val}{Val}
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
β-Amyloid 35-42
β-Amyloid (35-42) is a peptide consisting of amino acid of 35 to 42 of beta amyloid protein.
-
β-amyloid 12-28
Amyloid β-peptide fragment; minimum section required to bind to brain proteins. Binds with high affinity to α7-nicotinic ACh receptors, and impairs memory retention following central administration in mice in vivo.
-
Aducanumab
Aducanumab (BIIB037), A selective human immunoglobulin gamma-1 (IgG1) monoclonal antibody, targets the clustered form of amyloid beta (Aβ). Aducanumab shows brain permeability and may be used to treat Alzheimer's disease (AD).
